PolyPeptide Group AG PPGN
SIX · Switzerland · Health Technology
CHF 44.100.00 (0.00%)
Market open· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), through its direct Swiss subsidiary Samsung Peptide AG ("Samsung Peptide"), today published the tender offer prospectus ("Offer Prospectus") for all publicly held registered shares of PolyPeptide Group AG ("PolyPeptide").
Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensional, long-term growth strategy across capacity, portfolio, and geographic expansion.
PolyPeptide Group AG (PLYGF) upgrades 2026 guidance amid strong metabolic drug demand and a proposed acquisition by Samsung Biologics.
Completion of the deal is anticipated towards the end of 2026.
Samsung Biologics (KRX: 207940.KS) today announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG ("PolyPeptide") (ISIN CH1110760852, ticker symbol: PPGN), a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs).
ZOFINGEN, SWITZERLAND - June 1, 2026 (NEWMEDIAWIRE) - Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, appoints Christina Del Vecchio as Chief Legal Officer and me...
EQT, IDG Capital and Altaris are pursuing PolyPeptide as due diligence and bid discussions continue.
Swiss drugmaker reviews options after takeover interest reports, highlighting early-stage discussions with no assurance of outcome
Private equity circles a niche pharma player that’s quietly become more valuable than it looks.
KKR is facing a wave of investor redemption requests in its private credit funds, prompting withdrawal limits similar to those seen at other large asset managers. The redemption pressure highlights client concerns around liquidity in private markets and the structure of semi-liquid credit vehicles. At the same time, KKR is reported to be exploring an acquisition of PolyPeptide Group, a move that would extend its reach in pharmaceutical and biotech services. For investors watching NYSE:KKR,...
BAAR, SWITZERLAND - April 8, 2026 (NEWMEDIAWIRE) - PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all proposals put forward by the Bo...
PolyPeptide Group AG (PLYGF) reports a 16% revenue increase and significant EBITDA margin improvement, while navigating challenges and setting ambitious growth targets for 2026.
BAAR, CH / ACCESS Newswire / January 19, 2026 /PolyPeptide Group AG (SIX:PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful closing of its financial year 2025. Highlights PolyPeptide ...
CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical customers in the U.S. The colla
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.